



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708. Phone : 0091-11-26494519-24

CIN : L74899DL1978PLC009181


JPL/Stock-Corr-2013	November 11th, 2016
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager Listing Agreement The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote : JAGSNPHARM	Scrip Code : 507789
OUT-COME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON 11.11.2016	

Sir,

- Performance of the 2nd Quarter and Half Year ended 30.09.2016 (Un-audited) was placed before the Board having reviewed by the Audit Committee. The issue was discussed.
- Approval of 2nd Quarter and Half Year performance ended 30.09.2016 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meetings commence at 12.00 noon and concluded at 2.15 p.m.

Thanking you,

Yours faithfully,
For JAGSONPAL PHARMACEUTICALS LIMITED


R K KAPOOR
COMPLIANCE OFFICER & COMPANY SECRETARY





JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

JAGSONPAL PHARMACEUTICALS LIMITED

Extract of Unaudited Financial Results for the Quarter ended 30th September, 2016

Rs. in lacs

S_No.	Particulars	Quarter	Quarter	Quarter	6 Monthly	6 Monthly	12 Months
		Ended 30-09-2016 Un-audited	Ended 30-06-2016 Un-audited	Ended 30-09-2015 Un-audited	Ended 30-09-2016 Un-audited	Ended 30-09-2015 Un-audited	Ended 31-03-2016 Audited
1	Total Income from operations (net)	4001.90	4011.02	3296.96	8012.92	6995.71	14348.79
2	Net Profit / (Loss) before Tax	62.93	80.17	59.85	143.10	123.00	407.52
3	Net Profit / (Loss) after Tax	50.33	64.14	43.95	114.47	90.40	325.42
4	Equity Share Capital (face Value Rs. 5/-)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
5	Reserves (excluding revaluation Reserves as shown in the Balance of Previous Year						7742.63
6	Earning per Shares (Rs.) (Face value : Rs. 5/- each) not annualized Basic & Diluted E P S						
	Before Extraordinary Item	0.19	0.24	0.17	0.44	0.35	1.24
	After Extraordinary Items	0.19	0.24	0.17	0.44	0.35	1.24

The above is an extract of the detailed format of Quarterly Financial Results filed with the stock Exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial results are available on the website of the Bombay Stock exchange Ltd. At <http://bseindia.com> and National Stock Exchanges of India Ltd. At <http://www.nseindia.com> and also on the Company's website at <http://www.jagsonpal.com>.

There are no exceptional & extraordinary items during the above periods.

for JAGSONPAL PHARMACEUTICALS LIMITED

Place : New Delhi
Date : 11/11/2016



RAJPAL SINGH KOCHHAR
Managing Director
DIN : 00059492



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter / Half year ended 30.09.2016

Rs. in lacs

Particulars	3 months	3 months	3 months	6 Months	6 Months	12 Months
	ended 30.09.2016 Unaudited	ended 30.06.2016 Unaudited	ended 30.09.2015 Unaudited	ended 30.09.2016 Unaudited	ended 30.09.2015 Unaudited	Ended 31.03.2016 Audited
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	4001.90	4011.02	3296.96	8012.92	6995.71	14348.79
b Other Operating Income	14.02	13.15	30.94	27.17	30.94	59.26
Total Income from operations (net)	4015.92	4024.17	3327.90	8040.09	7026.65	14408.05
2 Expenses						
a Cost of materials consumed	1212.16	1673.9	2164.71	2886.06	3474.73	5627.89
b Purchases of stock-in-trade	192.14	374.99	267.62	567.13	385.02	906.68
c. Changes in inventories of finished goods,	283.42	-422.43	-1147.36	-139.01	-640.27	-622.24
d. Employee benefits expenses	1011.44	1116.11	967.46	2127.55	1791.06	3783.71
e. Depreciation and amortisation expense	72.80	70.43	73.08	143.23	142.22	309.36
f. Other expenses	1094.02	1036.16	825.27	2130.18	1513.19	3471.80
Total expenses	3865.98	3849.16	3150.78	7715.14	6665.95	13477.20
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	149.94	175.01	177.12	324.95	360.70	930.85
4 Other Income	0.06	0.03	3.41	0.09	6.31	6.38
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	150.00	175.04	180.53	325.04	367.01	937.23
6 Finance Cost	87.07	94.87	120.68	181.94	244.01	529.71
7 Profit from ordinary activities after finance cost but before Exceptional items (5-6)	62.93	80.17	59.85	143.10	123.00	407.52
8 Exceptional Items						
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	62.93	80.17	59.85	143.10	123.00	407.52
10 Tax expense	12.60	16.03	15.90	28.63	32.60	82.10
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	50.33	64.14	43.95	114.47	90.40	325.42
12 Extraordinary Items (net of tax expense Rs.lacs)						
13 Net Profit(+)/Loss(-) for the period(11-12)	50.33	64.14	43.95	114.47	90.40	325.42
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr						7742.63
16 Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.19	0.24	0.17	0.44	0.35	1.24
b. Diluted (Rs.)	0.19	0.24	0.17	0.44	0.35	1.24

Notes

- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 11, 2016.
- 2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period
- 4) The above results are available on website of the company www.jagsonpal.com.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar

Rajpal Singh Kochhar
Managing Director
DIN No 00059492



Place : New Delhi
Date : 11.11.2016

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DLI978PLC009181

Statement of Assets and Liabilities

		Rs. In lacs				Rs. In lacs	
A	EQUITY AND LIABILITIES	As at 30.09.2016 Unaudited	As at 31.03.2016 Audited	B	ASSETS	As at 30.09.2016 Unaudited	As at 1.03.2016 Audited
1	Shareholders' funds			1	Non-current assets		
	(a) Share Capital	1309.90	1309.90		(a) Fixed Assets	5104.85	5158.41
	(b) Reserves and surplus	8641.02	8526.55		(b) Goodwill	3.00	3.00
	Sub-total - Shareholders' funds	9950.92	9836.45		(c) Non-current investments	0.05	0.05
2	Share application money pending allotment	0.00	0.00		(d) Deferred tax assets (net)	0.00	0.00
3	Minority interest	0.00	0.00		(e) Long term loans and advance	682.89	670.88
	Non-current liabilities				(f) Other non-current assets	0.00	0.00
	(a) Long term borrowings	0.00	0.00		Sub-total - Non-current assets	5790.79	5832.34
	(b) Deferred tax liabilities (net)	360.56	360.86	2	Current assets		
	(c) Other long term liabilities	0.00	0.00		(a) Current investments		
	(d) Long term provisions	0.00	0.00		(b) Inventories	4115.76	3983.75
	Sub-total - Non-current liabilities	360.56	360.86		(c) Trade receivables	4540.80	4169.02
5	Current liabilities				(d) Cash and Cash equivalents	1340.12	1553.33
	(a) Short term borrowing	1473.29	3849.26		(e) Short term loans and advance	876.64	389.74
	(b) Trade payables	957.31	972.68		(f) Other current assets	0.00	0.00
	(c) Other current liabilities	3645.77	661.30		Sub-Total - Current assets	10873.32	10095.84
	(d) Short term provisions	276.26	247.63				
	Sub-Total - Current liabilities	6352.63	5730.87				
	TOTAL - EQUITY AND LIABILITIES	16664.11	15928.18		TOTAL - ASSETS	16664.11	15928.18



Ravesh

The Board of Director
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat
New Delhi - 110049

SUBJECT: LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") the Quarter ended 30.09.2016 which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the Quarter ended 30th September, 2016" (the "statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI, 2015 (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations 2015) which has been initialed by us for identification purposes.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review of Interim Financial Information Performed by Independent Auditor of the entity" by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) rule 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO.,
Chartered Accountants



Place : New Delhi
Date : 11.11.2016

SURESH SETHI
PARTNER
F.R. No. 000632N
Membership No. 89318